Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

At a median follow-up of 24.5 months, overall survival was 63.8% for patients assigned to ipilimumab plus nivolumab vs 53.6% for those on ipilimumab alone. Median overall survival had not been reached in either group (HR 0.74, 95% CI 0.43–1.26; p=0.26).

A related editorial discusses the findings of this study.

 

The National Institute for Health and Care Excellence (NICE) has recommended nivolumab in combination with ipilimumab, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults, only when the company provides ipilimumab with the discount agreed in the patient access scheme.